Nerve Cell Articles & Analysis
28 news found
MSA is characterized histopathologically by abnormal deposits of the α-synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve cells. ...
“In addition, positive study outcomes from our cell & gene therapy platforms offer a potential upside that is hard to quantify exactly today but can reach multi-billion Euro ...
ByBayer AG
CD Bioparticles now offers various options for researchers in Sphingomyelin, for example, the N-acetyl-D-erythro-sphingosylphosphorylcholine (Catalog: CDLP-A1144). As a major constituent of cell membranes, sphingomyelin is found at particularly high concentrations in the membranes of nerve cells (in myelin sheaths) and red blood ...
Glioblastoma is a type of glioma, which is a brain tumor that begins in the star-shaped glial cells that surround and support nerve cells in the brain. GBM is a Grade IV type of brain tumor. ...
AstroRx® has shown to support the nerve cells in the central nervous system, including the brain and spinal cord. ...
NESS ZIONA, ISRAEL, March 3, 2022 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant from the Israel Innovation Authority (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million). ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as motor neuron diseases. ...
Prior to Cellerant, he worked in the Process Sciences group at Cell Genesys. During this period, Dr. Banik held a number of positions with increasing responsibility including leading the development of manufacturing processes and scale up to commercial scale for cell therapy products such as GVAX immunotherapy. ...
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as motor neuron diseases. ...
“The NRTX-1001 preclinical data package is compelling, supporting clinical development of a novel cell therapy designed to provide targeted inhibition to hyperexcitable neural networks in the epileptic brain,” said Dr. ...
Extracellular vesicles are vesicle-like bodies with a double-layer membrane structure that fall off the cell membrane or are secreted by cells, and are mainly composed of microvesicles, apoptotic bodies, and exosomes. ...
DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study. ...
“Our objective is to use authentic cells, to have them integrate entirely into the brain and restore lost physiologic function. ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. ...
Professor Ann Logan, from the University of Warwick, leader of the research team and senior author of the publication, said, “Inflammation plays a vital role in healing, but when it becomes uncontrolled the immune system starts damaging healthy cells, tissues, and organs causing scarring that compromises function. Excessive inflammation has adverse consequences in the brain ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. ...
The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and degenerative neurological diseases and cell transplantation. “We are delighted to have secured this funding, which shows the confidence our shareholders have in our unique drug ...
” “For KLS-13019 treatment of CIPN, significant progress has been made in identifying a molecular mechanism of protection from the complex effects of paclitaxel-induced damage of sensory nerve cells,” stated Dr. Brenneman. The completed study could lead to a Phase 2 grant and further advances Kannalife’s belief that KLS-13019 could ...